Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
Better predictor than (unadjusted) serum PSA for: | Better predictor than (unadjusted) serum PSA for: | ||
*Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref> | *Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref> | ||
*BPH versus cancer.<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref> | |||
====A forumla for PSAD==== | ====A forumla for PSAD==== | ||
*Benson:<ref>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref> | *Benson ''et al.'':<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref> | ||
:<math>PASD = \frac{serum PSA}{volume}</math> | :<math>PASD = \frac{serum PSA}{volume}</math> | ||
**Where | **Where | ||
Revision as of 04:21, 30 July 2014
Prostate specific antigen, abbreviated PSA, is marker that is quite specific for the prostate.
General
- Quantity in the serum used to screen for prostate cancer.
- PSA immunostain useful for classifying a carcinoma as prostate carcinoma.
Serum PSA
- Normal - typically < 4.0 ng/mL.
- Increases with age.[1]
Prostate specific antigen density
- Abbreviated PSAD.
Better predictor than (unadjusted) serum PSA for:
- Gleason score upgrading on prostatectomy.[2]
- BPH versus cancer.[3]
A forumla for PSAD
- Benson et al.:[3]
- Where
- D1, D2, D3 are the major axes.
Note:
- The volume of an ellipsoid is:
See also
References
- ↑ Ku JH, Ahn JO, Lee CH, et al. (September 2002). "Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity". Urology 60 (3): 475–9. PMID 12350489.
- ↑ Sfoungaristos S, Katafigiotis I, Perimenis P (2013). "The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era". Can Urol Assoc J 7 (11-12): E722–7. doi:10.5489/cuaj.374. PMC 3840515. PMID 24282465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840515/.
- ↑ 3.0 3.1 Benson MC, Whang IS, Pantuck A, et al. (March 1992). "Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer". J. Urol. 147 (3 Pt 2): 815–6. PMID 1371554.